1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Medicamen Biotech Limited

Medicamen Biotech Limited

MEDICAMEQ.BO
Medicamen Biotech LimitedIN flagBombay Stock Exchange
247.55
INR
+2.55
- -
3.36BMarket Cap
Medicamen Biotech Limited
MEDICAMEQ.BO
(Bombay Stock Exchange)

Recent

price

247.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
159.14
127.28
76.41
86.26
86.14
67.84
79.1
99.57
104.81
103.3
92.26
94.5
111.35
141.64
127.84
- -
141.45
Revenue per Share
3.59
-1.04
-5.88
0.11
0.49
0.48
4.95
9.03
10.28
10.94
9.93
12.19
11.73
8.63
5.59
- -
7.38
Basic EPS, GAAP
9.65
-6.47
-3.38
4.9
-3.73
5.06
1.22
-12.18
-9.73
-20.42
-4.25
-3.68
-10.19
-10.29
-8.14
- -
- -
Free Cash Flow per Basic Share
0.75
- -
- -
- -
- -
- -
- -
0.99
- -
1.01
0.5
1
1
1
1
- -
- -
Dividend per Share
10.21
23.34
16.42
16.81
16.42
16.13
20.8
28.08
37.16
45.93
55.11
66.3
75.24
81.74
85.75
- -
9.7
Book Value per Share
26.24
25.26
18.63
19.39
18.98
18.03
25.67
66.34
73.77
99.55
108.61
119.6
152.17
162.79
166.98
- -
196.67
Tangible Book Value per Share
8
8
8
8
9
10
10
11
12
12
12
12
13
13
13
- -
14
Basic Weighted Avg Shares
1,230
1,005
640
732
778
673
825
1,115
1,226
1,255
1,127
1,154
1,409
1,793
1,625
1,978
1,978
Sales/Revenue/Turnover
3.75
1.19
-2.87
4.94
3.82
5.4
11.72
13.22
12.6
13.76
15.22
16.46
13.41
9.71
4.18
6.25
6.25
Operating Margin (%)
14
15
16
16
21
19
19
21
22
25
25
58
64
71
69
72
72
Depreciation Expense
28
-8
-49
1
4
5
52
101
120
133
121
149
148
109
71
96
103
Net Income, GAAP
35.53
- -
- -
47.3
- -
32.45
18.85
27.25
31.37
26.08
26.01
17.67
13.59
27.39
33.65
18.26
18.26
Effective Tax Rate (%)
2.26
-0.82
-7.7
0.13
0.57
0.71
6.26
9.07
9.81
10.59
10.76
12.9
10.54
6.1
4.37
4.88
5.21
Profit Margin (%)
-5
-18
-58
-37
38
34
107
498
476
476
428
503
808
750
864
1,358
1,358
Working Capital
9
2
2
2
46
35
25
1
- -
24
64
51
9
13
37
62
62
LT Debt
204
201
157
165
172
179
268
746
866
1,212
1,329
1,465
1,934
2,070
2,131
2,756
2,756
Total Equity
10.28
- -
- -
5.9
- -
6.52
18.88
15.91
11.31
11.05
8.78
9.28
8.01
5.39
1.83
3.51
3.51
Return on Invested Capital (%)
21.33
- -
- -
5.37
- -
7.26
20.39
27.84
25.05
22.39
16.84
16.64
15.35
12.09
6.96
12.02
13.33
Return on Capital (%)
35.58
-6.27
-30.62
0.67
3.03
3.12
27.39
38.07
32.11
26.78
19.7
20.09
16.85
11
6.69
15.73
16.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
350
- -
416
LT Borrowings
36
- -
62
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
- -
14
Market Capitalization
4,411
5,501
3,141

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,234
- -
2,237
Cash, Cash Equivalents & STI
437
- -
313
Accounts Receivable, Net
776
- -
818
Inventories
688
- -
701
Total Current Liabilities
856
- -
879
Payables & Accruals
- -
- -
- -
ST Debt
350
- -
416
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.54%
16.31%
29.33%
Free Cash Flow
-80.37%
84.09%
266.76%
Net Income, GAAP
108.65%
-0.65%
35.64%
Sales/Revenue/Turnover
12.4%
12.81%
21.67%
Total Cash Common Dividend
- -
- -
6.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
419
435
465
473
1,793
2025
430
447
451
296
1,625
2026
430
472
469
606
1,978

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.3
1.17
1.6
- -
8.63
2025
1.06
1.15
2.3
1.47
5.59
2026
1.59
1.56
1.21
3.28
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -
Similar Companies
Lansen Pharmaceutical Holdings Limited (0503.HK)
Haleon plc (HLNCF)
Lannett Company, Inc. (LCI)
Eden Empire Inc. (EDNEF)
TerrAscend Corp. (TRSSF)
Cannasouth Limited (CBD.NZ)
Business
Medicamen Biotech Limited, a research-led pharmaceutical company, develops, manufactures, and markets finished dosage formulations across oncology, cardiology, diabetology, central nervous system disorders, pain management, anti-infectives, vitamins, anti-malarials, cough and cold, gastrointestinal, anti-allergic, and cardiovascular therapeutic areas; its core products include sterile oncology injectables such as Bortezomib, tablets, capsules, oral liquids, ointments, and creams with over 160 registered products and 280 under filing, supplied through branded marketing via subsidiary Medicamen Lifesciences focusing on anti-hypertensives, antidiabetics, and cardiology treatments. Founded in 1993 and headquartered in New Delhi, India, the company operates manufacturing facilities in Bhiwadi (Rajasthan; EU GMP certified), Haridwar Unit I (Uttarakhand; general formulations), and Haridwar Unit II (Uttarakhand; USFDA-approved sterile oncology), with vertically integrated R&D, APIs, and formulations serving over 35 countries in Latin America, Africa, Asia-Pacific, Europe, MENA, and emerging regulated markets like the US, Canada, and Australia. Recent developments include a 10-year manufacturing and supply agreement with a leading US and European pharma distributor for its USFDA-approved oncology unit in February 2025; a CDMO contract with European firm XGX Pharma in April 2025 to develop and manufacture six products retaining market authorization rights in Europe; launch of 12 oncology products now available in 16 Indian cities supplying Tata Memorial, AIIMS, Max, and Fortis hospitals; first USFDA ANDA filing for Bortezomib injection and seven EU filings with four more in development; initiation of domestic oncology marketing and operations at Haridwar Unit II oncology facility; EU market preparations for 10 non-oncology formulations; and certifications including USFDA approval for its sterile oncology plant enabling US and Middle East expansion, alongside Bhiwadi's EU GMP from Greece's National Organisation for Medicines.